In general, the absence or the lower E-cadherin expression in ovarian cancers predicts poor patient survival when compared with ovarian tumors that express E-cadherin and correlates with high tumor grade and low overall survival rate [81]. This evidence concerns the gene CDH1 and ovarian carcinoma.